EnterNext welcomes Curetis on Euronext Amsterdam and Euronext Brussels

EnterNext welcomes Curetis on Euronext Amsterdam and Euronext Brussels

EnterNext welcomes Curetis on Euronext Amsterdam and Euronext Brussels

The FINANCIAL -- EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for SMEs, on November 11 celebrated the listing of Curetis N.V., a developer of next-level molecular diagnostic solutions. Curetis listed on Euronext Amsterdam and Euronext Brussels.

Founded in 2007, Curetis AG is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions offered by Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker detection in a few hours, a process that today can take up to days or even weeks with other techniques. Curetis has signed collaboration agreements with Heraeus Medical and Cempra Inc. as well as several international distribution agreements covering countries across Europe, the Middle East and Asia, according to Euronext.

The issue price of Curetis was set at € 10.00 per share. Market capitalization was € 151 million on the day of listing. The offering raised € 40 million altogether.

Oliver Schacht, CEO of Curetis said: “The IPO is a major milestone in Curetis´ corporate history and we are proud to join the group of renowned healthcare companies listed on Euronext. The proceeds of the transaction will mainly be used to expand the commercialization of our Unyvero Platform and to expand our product portfolio to address additional infectious diseases.”

Maurice van Tilburg, CEO of Euronext Amsterdam said: “We’re delighted to welcome Curetis today as part of its IPO and dual-listing on Euronext Amsterdam and Brussels. The dual-listing gives the company optimal visibility and exposure in both respective markets. The diversity of investors and combined liquidity in both markets offer Curetis strong access to capital which will help execute its strategy and support further development.”

Vincent van Dessel, CEO of Euronext Brussels: “We are happy to partner with Curetis as it enters in a new phase of its development. The company now benefits from strong financing solutions on Europe’s most active market for life sciences. The unique offering of multiple listing venues across our markets will help Curetis to create optimal conditions to enhance its visibility and liquidity as public traded stock.”

Albert Ganyushin, Head of International Listings of Euronext added: “Curetis’ transaction is the second German company completing an IPO and the fourth international life sciences IPO on our markets recently and is a testament to the strength, resilience and growing international profile of our life science franchise. Including Curetis, Euronext has listed 15 IPOs of European life science companies since the start of 2015. We are delighted, especially considering the market volatility, that the potential of the diagnostic solutions developed and commercialized by Curetis has been recognized by the public market investors. This transaction demonstrates the capacity of Euronext markets to finance growth of European life science companies and the strength of our internationally established broker community focused on serving the European healthcare industry.”

To mark the listing, Curetis sounded the gong in Amsterdam to open the financial market.